Use of trastuzumab emtansine (T-DM1; K) after pertuzumab plus trastuzumab (PH) in patients with HER2-positive metastatic breast cancer (mBC): Challenges in assessing effectiveness of treatment sequencing in the real world (RW)

被引：0
|
作者：
Sanglier, T. [1 ]
Fabi, A. [2 ]
Flores, C. [3 ]
Flahavan, E. [4 ]
Lindegger, N. [5 ]
Montemurro, F. [6 ]
机构：
[1] F Hoffmann La Roche Ltd, RWD Oncol, Basel, Switzerland
[2] Ist Nazl Tumori Regina Elena, Oncol Med, Rome, Italy
[3] Genentech Inc, RWD Oncol, San Francisco, CA 94080 USA
[4] F Hoffmann La Roche Ltd, RWD Oncol, Welwyn Garden City, Herts, England
[5] F Hoffmann La Roche Ltd, Med Affairs Oncol, Global Prod Dev, Basel, Switzerland
[6] Candiolo Canc Inst, Day Hosp Oncol Multidisciplinare, Candiolo, Italy
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
356P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Trastuzumab Emtansine (T-DM1) Plus S-1 in Patients with Trastuzumab-Pretreated HER2-Positive Advanced or Metastatic Breast Cancer: A Phase Ib Study
    Kojima, Yasuyuki
    Yoshie, Reiko
    Kawamoto, Hisanori
    Shimo, Arata
    Uejima, Tomoko
    Iwatani, Tsuguo
    Motoyoshi, Ai
    Kanemaki, Yoshihide
    Boku, Narikazu
    Tsugawa, Koichiro
    ONCOLOGY, 2019, 96 (06) : 309 - 317
  • [32] Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases
    Jacot, William
    Pons, Elvire
    Frenel, Jean-Sebastien
    Guiu, Severine
    Levy, Christelle
    Heudel, Pierre Etienne
    Bachelot, Thomas
    D'Hondt, Veronique
    Darlix, Amelie
    Firmin, Nelly
    Romieu, Gilles
    Thezenas, Simon
    Dalenc, Florence
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 157 (02) : 307 - 318
  • [33] Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases
    William Jacot
    Elvire Pons
    Jean-Sébastien Frenel
    Séverine Guiu
    Christelle Levy
    Pierre Etienne Heudel
    Thomas Bachelot
    Véronique D’Hondt
    Amélie Darlix
    Nelly Firmin
    Gilles Romieu
    Simon Thezenas
    Florence Dalenc
    Breast Cancer Research and Treatment, 2016, 157 : 307 - 318
  • [34] T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study
    Conte, Benedetta
    Fabi, Alessandra
    Poggio, Francesca
    Blondeaux, Eva
    Dellepiane, Chiara
    D'Alonzo, Alessia
    Buono, Giuseppe
    Arpino, Grazia
    Magri, Valentina
    Naso, Giuseppe
    Presti, Daniele
    Mura, Silvia
    Fontana, Andrea
    Cognetti, Francesco
    Molinelli, Chiara
    Pastorino, Simona
    Bighin, Claudia
    Miglietta, Loredana
    Boccardo, Francesco
    Lambertini, Matteo
    Del Mastro, Lucia
    CLINICAL BREAST CANCER, 2020, 20 (02) : E181 - E187
  • [35] Efficacy and safety of trastuzumab emtansine (T-DM1) in the treatment of HER2-positive metastatic breast cancer (MBC): a meta-analysis of randomized controlled trial
    Yan, Hongjing
    Yu, Kewei
    Zhang, Kaile
    Liu, Linxia
    Li, Yue
    ONCOTARGET, 2017, 8 (60) : 102458 - 102467
  • [36] PHASE I STUDY OF TRASTUZUMAB EMTANSINE (T-DM1) IN HER2-POSITIVE METASTATIC BREAST CANCER (MBC) PATIENTS WITH NORMAL OR REDUCED HEPATIC FUNCTION.
    Agarwal, P.
    Li, C.
    Gibiansky, L.
    Dent, S.
    Goncalves, A.
    Nijem, I.
    Strasak, A.
    Lorusso, P.
    Girish, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S21 - S21
  • [37] The evolving role of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer with brain metastases
    Dong, Rongrong
    Ji, Jiali
    Liu, Hong
    He, Xuexin
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 143 : 20 - 26
  • [38] Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model
    Yamashita-Kashima, Yoriko
    Shu, Sei
    Harada, Naoki
    Fujimoto-Ouchi, Kaori
    ONCOLOGY REPORTS, 2013, 30 (03) : 1087 - 1093
  • [39] The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer
    Delgado, J.
    Vleminckx, C.
    Sarac, S.
    Sosa, A.
    Bergh, J.
    Giuliani, R.
    Enzmann, H.
    Pignatti, F.
    ESMO OPEN, 2021, 6 (02)
  • [40] Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study
    Noguchi, Emi
    Tamura, Kenji
    Hattori, Masaya
    Horiguchi, Jun
    Sato, Nobuaki
    Kanatani, Kazumitsu
    Matsunaga, Kiyoshi
    Iwata, Hiroji
    Fujiwara, Yasuhiro
    BREAST CANCER, 2019, 26 (01) : 39 - 46
12345